Category

• Pipeline2
• Business1

Organizations

• Bausch + Lomb64
• Eyes On Eyecare45
• Alcon, Inc.43
• American Optometric Association35
• Harrow28
• Glaukos26
• Regeneron22
• Topcon Healthcare22
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Cornea2
• CEO1
• FDA1
• Clinical Trials1
• Eye Drop Solution1
• Eye Drops1
• Leadership1

• Organizations: KALA BIO✕

Clear all

Business

Leadership watch: KALA BIO names new CEO, Aurion Biotech promotes execs

Aurion makes its move ahead of initiating a phase 3 trial in early 2026 for its allogeneic cell therapy, under evaluation for corneal endothelial disease.

Pipeline

Kala's phase 2b PCED trial fails to meet primary goal

Company plans to cease development of lead asset KPI-012 as the CHASE study also falls short of achieving statistical significance for secondary endpoints.

Pipeline

FDA grants Fast Track designation to KPI-012 for PCED

Kala Pharmaceuticals’ lead product candidate is a human MSC-S therapy.